The current meta-analysis demonstrated that the addition of metformin was beneficial for diabetic NSCLC patients who received EGFR-TKI therapy and that metformin use could significantly improve the survival rate of this group of patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.